RESPONSIBILITIES OF UNIVERSITY INVESTIGATORS WHEN CONDUCTING TRIALS ON INVESTIGATIONAL NEW ANIMAL DRUGS

被引：0

|

作者：

PARROTT, JC

机构：

来源：

JOURNAL OF ANIMAL SCIENCE | 1987年 / 65卷 / 02期

关键词：

D O I：

10.2527/jas1987.652577x

中图分类号：

S8 [畜牧、动物医学、狩猎、蚕、蜂];

学科分类号：

0905 ;

摘要：

引用

收藏

页码：577 / 580

页数：4

相关论文

共 27 条

[21] Investigation of the Factors Affecting Risk-Based Quality Management of Investigator-Initiated Investigational New-Drug Trials for Unapproved Anticancer Drugs in Japan
Tomohisa Sudo
Akihiro Sato
Therapeutic Innovation & Regulatory Science, 2017, 51 : 589 - 596
[22] Investigation of the Factors Affecting Risk-Based Quality Management of Investigator-Initiated Investigational New-Drug Trials for Unapproved Anticancer Drugs in Japan
Sudo, Tomohisa
Sato, Akihiro
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (05) : 589 - 596
[23] Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs
Fulkerson, Christopher M.
Dhawan, Deepika
Ratliff, Timothy L.
Hahn, Noah M.
Knapp, Deborah W.
INTERNATIONAL JOURNAL OF GENOMICS, 2017, 2017
[24] Is it ethical conducting placebo-controlled clinical trials as part of the development of new drugs for the treatment of major depressive disorder?: (I).: Considerations on the value and scientific validity of the study
Gracia, D
Lahuerta, J
Carné, X
Dal-Ré, R
MEDICINA CLINICA, 2004, 123 (14): : 546 - 550
[25] Is it ethical conducting placebo-controlled clinical trials as part of the development of new drugs for the treatment of major depressive disorder? (and II). Benefit/risk, ratio and informed consent. Conclusions
Lahuerta, J
Gracia, D
Casas, M
Baca, E
MEDICINA CLINICA, 2004, 123 (15): : 585 - 590
[26] Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: A report from the William Guy Forbeck Foundation 2001 Focus Meeting on clinical stem cell transplantation
Martin, PJ
Antin, JH
Weisdorf, DJ
Paton, V
Horowitz, MM
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (06) : 295 - 302
[27] How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.
Massari, Francesco
Maines, Francesca
Pilotto, Sara
Porta, Camillo
Carlini, Paolo
Modena, Alessandra
Ciccarese, Chiara
Sperduti, Isabella
Giannarelli, Diana
Tortora, Giampaolo
Bria, Emilio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)